Featured
-
-
Article |
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma
- Dong-yang Ding
- , Xiao-jie Gan
- & Sheng-xian Yuan
-
Article
| Open Access
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
- Aurelie Tomczak
- , Christoph Springfeld
- & Thomas Longerich
-
Article
| Open Access
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
- Olaf Neumann
- , Timothy C. Burn
- & Daniel Kazdal
-
Article
| Open Access
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells
- Guoying Zhou
- , Ruby Lieshout
- & Jaap Kwekkeboom
-
Article
| Open AccessExogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank
- Jessica L. Petrick
- , Úna C. McMenamin
- & Katherine A. McGlynn
-
Article
| Open Access
SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance
- Xiaodong Yuan
- , Jun Li
- & Hong-Lei Weng
-
Article
| Open Access
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- Vincenzo Mazzaferro
- , Bassel F. El-Rayes
- & Walid L. Shaib
-
Article
| Open Access
Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
- Benjamin Goeppert
- , Stephanie Roessler
- & Matthias Kloor
-
Article
| Open Access
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
- Alison C. Backen
- , Andre Lopes
- & Juan W. Valle
-
Clinical Study
| Open Access
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Clinical Study
| Open AccessValidation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder
- S D Kaupp-Roberts
- , G Yadegarfar
- & J K Ramage
-
Molecular Diagnostics
| Open Access
Prognostic significance of epithelial–mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray
- T Nitta
- , T Mitsuhashi
- & Y Matsuno
-
Clinical Study
| Open Access
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy
- H Sasaki
- , Y Murakami
- & T Sueda
-
Molecular Diagnostics
| Open Access
Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis
- F Peng
- , J Jiang
- & R Qin
-
Molecular Diagnostics
| Open Access
E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
- K Araki
- , T Shimura
- & H Kuwano
-
Molecular Diagnostics
| Open Access
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- M Miyamoto
- , H Ojima
- & T Shibata
-
Molecular Diagnostics
| Open Access
CpG-island methylation study of liver fluke-related cholangiocarcinoma
- R Sriraksa
- , C Zeller
- & T Limpaiboon
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy